Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021

The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Harder, Thomas, Külper-Schiek, Wiebe, Reda, Sarah, Treskova-Schwarzbach, Marina, Koch, Judith, Vygen-Bonnet, Sabine, Wichmann, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518304/
https://www.ncbi.nlm.nih.gov/pubmed/34651577
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.41.2100920
_version_ 1784584195336568832
author Harder, Thomas
Külper-Schiek, Wiebe
Reda, Sarah
Treskova-Schwarzbach, Marina
Koch, Judith
Vygen-Bonnet, Sabine
Wichmann, Ole
author_facet Harder, Thomas
Külper-Schiek, Wiebe
Reda, Sarah
Treskova-Schwarzbach, Marina
Koch, Judith
Vygen-Bonnet, Sabine
Wichmann, Ole
author_sort Harder, Thomas
collection PubMed
description The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19.
format Online
Article
Text
id pubmed-8518304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-85183042021-11-02 Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021 Harder, Thomas Külper-Schiek, Wiebe Reda, Sarah Treskova-Schwarzbach, Marina Koch, Judith Vygen-Bonnet, Sabine Wichmann, Ole Euro Surveill Rapid Communication The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19. European Centre for Disease Prevention and Control (ECDC) 2021-10-14 /pmc/articles/PMC8518304/ /pubmed/34651577 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.41.2100920 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Harder, Thomas
Külper-Schiek, Wiebe
Reda, Sarah
Treskova-Schwarzbach, Marina
Koch, Judith
Vygen-Bonnet, Sabine
Wichmann, Ole
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title_full Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title_fullStr Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title_full_unstemmed Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title_short Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
title_sort effectiveness of covid-19 vaccines against sars-cov-2 infection with the delta (b.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 january to 25 august 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518304/
https://www.ncbi.nlm.nih.gov/pubmed/34651577
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.41.2100920
work_keys_str_mv AT harderthomas effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT kulperschiekwiebe effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT redasarah effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT treskovaschwarzbachmarina effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT kochjudith effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT vygenbonnetsabine effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021
AT wichmannole effectivenessofcovid19vaccinesagainstsarscov2infectionwiththedeltab16172variantsecondinterimresultsofalivingsystematicreviewandmetaanalysis1januaryto25august2021

Ejemplares similares